Clinical Trials

Status
Published

1466 Results

Open
Phase
II
Accrual
0%
SWOG Clinical Trial Number
S1922

Randomized Phase II Study of Ramucirumab and Paclitaxel versus FOLFIRI in Refractory Small Bowel Adenocarcinoma

Status Notes
The study referenced above is open for participation effective Monday, December 16, 2019 at 2:00 p.m. Eastern.
Research Committee(s)
Gastrointestinal Cancer
Activated
12-16-2019
Open
SWOG Clinical Trial Number
CTSU/A071701

GENOMICALLY-GUIDED TREATMENT TRIAL IN BRAIN METASTASES

Status Notes
Step 0 & Step 1 Activation Effective 8/15/19; SWOG Activation Effective 9/1/19
Research Committee(s)
Brain Cancer
Activated
09-01-2019
ClinicalTrials.gov Registry Number
NCT03994796
Open
Phase
III
SWOG Clinical Trial Number
CTSU/NRG-BR004

A Randomized, Double-Blind, Phase III Trial of Paclitaxel/Trastuzumab/Pertuzumab with Atezolizumab or Placebo in First-Line HER2-Positive Metastatic Breast Cancer

Status Notes
Activated by NRG Oncology on 3/12/19.
Activated by SWOG: 7/24/2019
Research Committee(s)
Breast Cancer
Activated
07-24-2019
ClinicalTrials.gov Registry Number
NCT03199885
Open
Phase
SWOG Clinical Trial Number
CTSU/A011202

A Randomized Phase III Trial Comparing Axillary Lymph Node Dissection to Axillary Radiation in Breast Cancer Patients (cT1-3 N1) Who Have Positive Sentinel Lymph Node Disease After Neoadjuvant Chemotherapy

Status Notes
ALLIANCE activated: 2/7/14
SWOG activated: 7/24/19
Research Committee(s)
Breast Cancer
Activated
07-24-2019
ClinicalTrials.gov Registry Number
NCT01901094
Open
SWOG Clinical Trial Number
CTSU/A221405

A Study Evaluating the Pregnancy Outcomes and Safety of Interrupting Endocrine Therapy for Young Women with Endocrine Responsive Breast Cancer who Desire Pregnancy

Status Notes
Alliance activated: 10/15/15
SWOG activated: 7/27/19
Research Committee(s)
Breast Cancer
Activated
07-24-2019
ClinicalTrials.gov Registry Number
NCT02308085
Open
Phase
SWOG Clinical Trial Number
CTSU/EA1131

A Randomized Phase III Post-Operative Trial of Platinum Based Chemotherapy Vs. Capecitabine in Patients with Residual Triple-Negative Breast Cancer following Neoadjuvant Chemotherapy

Status Notes
ECOG-ACRIN activated: 4/29/2015
SWOG activated: 7/24/19
Research Committee(s)
Breast Cancer
Activated
07-24-2019
ClinicalTrials.gov Registry Number
NCT02445391
Open
Phase
SWOG Clinical Trial Number
CTSU/EA1151

Tomosynthesis Mammographic Imaging Screening Trial (TMIST)

Status Notes
ECOG-ACRIN Cancer Research Group activated: 7/6/17
SWOG activated: 7/24/19
Research Committee(s)
Breast Cancer
Activated
07-24-2019
ClinicalTrials.gov Registry Number
NCT03233191
Open
Phase
SWOG Clinical Trial Number
CTSU/NSABP-B-51
Open
Phase
SWOG Clinical Trial Number
CTSU/NRG-BR002

A Phase IIR/III Trial of Standard of Care Therapy with or without Stereotactic Body Radiotherapy (SBRT) and/or Surgical Ablation for Newly Oligometastatic Breast Cancer

Status Notes
Activated by NRG Oncology on 12/24/2014.
Activated by SWOG: 7/19/2019

TEMPORARILY CLOSED TO ACCRUAL EFFECTIVE 09/13/2019
Research Committee(s)
Breast Cancer
Activated
07-19-2019
ClinicalTrials.gov Registry Number
NCT02364557
Open
Phase
Accrual
3%
SWOG Clinical Trial Number
S1826

A Phase III, Randomized Study of Nivolumab (Opdivo) Plus AVD or Brentuximab Vedotin (Adcetris) Plus AVD in Patients (Age >/= 12 years) with Newly Diagnosed Advanced Stage Classical Hodgkin Lymphoma

Status Notes
Activation - Effective 7/19/19
Research Committee(s)
Lymphoma
Activated
07-19-2019
ClinicalTrials.gov Registry Number
03907488
Open
Phase
Accrual
4%
Open
Accrual
0%
SWOG Clinical Trial Number
S1916

Feasibility of a Digital Medicine Program in Optimizing Opioid Pain Control in Cancer Patients

Research Committee(s)
Cancer Care Delivery
Activated
06-11-2019
Open
SWOG Clinical Trial Number
CTSU/NHLBI-MDS

The National Myelodysplastic Syndromes (MDS) Study

Research Committee(s)
Prevention & Epidemiology
Leukemia
Activated
06-01-2019
ClinicalTrials.gov Registry Number
NCT02775383
Open
Accrual
39%
SWOG Clinical Trial Number
S1800A

A PHASE II RANDOMIZED STUDY OF RAMUCIRUMAB PLUS MK3475 (PEMBROLIZUMAB) VERSUS STANDARD OF CARE FOR PATIENTS PREVIOUSLY TREATED WITH IMMUNOTHERAPY FOR STAGE IV OR RECURRENT NON-SMALL CELL LUNG CANCER (LUNG-MAP NON-MATCHED SUB-STUDY)

Status Notes
S1800A will open to accrual May 17, 2019, effective 11:00 am PST.

This is an FDA registration study. There will be additional centralized and on-site monitoring conducted in addition to routine audits. Sites must also maintain a study specific Trial Master File for this study (https://swog.org/Visitors/QA/Index.asp).
Research Committee(s)
Lung Cancer
Activated
05-17-2019
Open
Phase
III
Accrual
5%
SWOG Clinical Trial Number
S1806
Open
Phase
Accrual
11%
SWOG Clinical Trial Number
S1714

A Prospective Observational Cohort Study to Develop a Predictive Model of Taxane-Induced Peripheral Neuropathy in Cancer Patients

Status Notes
This study is active as of 3/1/19.
Research Committee(s)
Symptom Control and Quality of Life
Breast Cancer
Lung Cancer
Early Therapeutics & Rare Cancers
Activated
03-01-2019
Open
Phase
SWOG Clinical Trial Number
CTSU/EAE161

Perfusion CT to Predict Progression-free Survival and Response Rate in Bevacizumab and Paclitaxel Treatment of Platinum-Resistant Persistent or Recurrent Epithelial Ovarian, Fallopian Tube, or Peritoneal Carcinoma

Status Notes
SWOG Activated/Championed CTSU/EAE161, effective March 1, 2019
Research Committee(s)
Early Therapeutics & Rare Cancers
Activated
03-01-2019
ClinicalTrials.gov Registry Number
NCT03412630